Bayer AG (OTC Pink - Current Information:BAYRY)
| 14.48 Delayed Data As of Nov 25 |  +0.29 / +2.04%Today’s Change | 11.41 Today|||52-Week Range 18.45 | +9.20% Year-to-Date |
Latest BAYRY News | Press Releases
| Regeneron (REGN) Outperforms YTD: What's in Store for 2023? Nov 25 / Zacks.com - Paid Partner Content | AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod Nov 14 / Zacks.com - Paid Partner Content |
| Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term Nov 23 / Zacks.com - Paid Partner Content | Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion Nov 14 / Zacks.com - Paid Partner Content |
| BAYRY vs. NVO: Which Stock Is the Better Value Option? Nov 16 / Zacks.com - Paid Partner Content | Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease Nov 14 / Zacks.com - Paid Partner Content |
| Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023? Nov 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 14.19 |
| Today’s open | 14.40 |
| Day’s range | 14.37 - 14.49 |
| Volume | 397,488 |
| Average volume (3 months) | 836,176 |
| Market cap | $56.9B |
Data as of 11/25/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +7.83% |
| Earnings growth (next 5 years) | +1.80% |
| Revenue growth (last year) | +10.40% |
| P/E ratio | -- |
| Price/Sales | 1.01 |
| Price/Book | 1.52 |
Competitors
| No competitors data available. |
Financials
| Next reporting date | February 28, 2023 |
| EPS forecast (this quarter) | $0.35 |
| Annual revenue (last year) | $52.1B |
| Annual profit (last year) | $1.2B |
| Net profit margin | 2.27% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Leverkusen, Nordrhein-westfalen |
Forecasts
Chart unavailable
